Benchmark Issues Pessimistic Forecast for CapsoVision (NASDAQ:CV) Stock Price

CapsoVision (NASDAQ:CV) had its target price lowered by analysts at Benchmark from $14.00 to $10.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “speculative buy” rating on the stock. Benchmark’s target price would indicate a potential upside of 33.16% from the company’s current price.

Several other analysts have also recently commented on the stock. Weiss Ratings reiterated a “sell (e)” rating on shares of CapsoVision in a research report on Monday, December 29th. Wall Street Zen upgraded CapsoVision to a “hold” rating in a research report on Saturday, January 10th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, CapsoVision presently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

CapsoVision Price Performance

Shares of NASDAQ:CV opened at $7.51 on Friday. CapsoVision has a one year low of $3.43 and a one year high of $15.37. The company has a 50 day moving average of $5.58 and a 200-day moving average of $6.27. The stock has a market cap of $351.77 million and a price-to-earnings ratio of -3.43.

CapsoVision (NASDAQ:CV) last announced its quarterly earnings data on Thursday, March 26th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $3.92 million during the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Deutsche Bank AG acquired a new position in CapsoVision during the fourth quarter valued at approximately $47,000. Wells Fargo & Company MN raised its holdings in CapsoVision by 66.4% in the fourth quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock worth $67,000 after purchasing an additional 2,508 shares during the period. New York State Common Retirement Fund bought a new position in shares of CapsoVision during the third quarter worth $34,000. Virtu Financial LLC acquired a new position in shares of CapsoVision in the 4th quarter valued at $128,000. Finally, Millennium Management LLC acquired a new position in shares of CapsoVision in the 4th quarter valued at $163,000.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.